Sanofi (Euronext: SAN) is presenting key updates to its R&D strategy and milestones for 2018 in Paris today.
Over the next few years, the company says it will shift away from small molecules to the development of biologics, with an emphasis on multi-targeting compounds.
In addition, the French drugmaker says it will increase emphasis on developing proprietary technology platforms, building on progress in multi-specific antibodies, siRNA, trigonal peptides, dual and triple agonists, and PRR-Antibody conjugates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze